Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vibostolimab (MK-7684) with or without pembrolizumab in advanced solid tumors
NCT02964013Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2016
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, open-label trial of vibostolimab in Neoplasm (11 arms), sponsored by Merck & Co. Primary endpoints: Dose Limiting Toxicities at 24 months, Adverse Events at 28 months and 1 more. Started Dec 2016; status: completed.
02
Drugs
vibostolimab
03
Conditions
Neoplasm
Beyond the preview
Go deeper on NCT02964013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02964013.